• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Aripiprazole Augmentation May Improve Remission Rates in MDD

Aripiprazole Augmentation May Improve Remission Rates in MDD

November 1, 2017
Ricardo Arechiga, PharmD candidate (2018)
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Ricardo Arechiga, PharmD candidate (2018) Mr. Arechiga has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Mohamed S et al, JAMA 2017;318(2):132–145

It seems like an endless debate: When a patient does not respond to the first trial of an antidepressant, what should we do? Switch to something else? Augment with another agent? If the latter, how often should that augmenting agent be an atypical antipsychotic? The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial was conducted to answer some of these questions. Specifically, the study compared the effectiveness and adverse effects of switching to bupropion SR, augmenting with bupropion SR, or augmenting with aripiprazole.

In this randomized controlled trial, 1,522 patients with non-psychotic major depressive disorder (MDD) who had failed at least one adequate 6-week course of an SSRI, an SNRI, or mirtazapine were recruited from the Veterans’ Administration (VA). Most of the patients were male (85%) and white (69%), and had an average age of 54.4. Patients were randomly assigned to one of three groups: switching to bupropion (most common dose 200 mg twice daily, n = 511), augmenting with bupropion (most common dose also 200 mg twice daily, n = 506), or augmenting with aripiprazole (most common dose 10 mg daily, n = 505). After 12 weeks of treatment, remission and response rates were: switch-bupropion: remission 22%, response 62%; augment-bupropion: remission 27%, response 66%; augment-aripiprazole: remission 29%, response 74%. Augmenting with aripiprazole yielded statistically superior remission rates than switching to bupropion (P = .02) and superior response rates than either of the bupropion arms. Somnolence, akathisia, and weight gain occurred more frequently in the aripiprazole group. Most dramatically, in a subset of patients who continued the trial for 36 weeks, 25% of the aripiprazole group gained at least 7% of body weight as opposed to only 5% of both bupropion groups.

TCPR’s Take
Aripiprazole augmentation was the most effective strategy for patients who had not responded to a single antidepressant trial, beating both switching to and augmenting with bupropion. While aripiprazole’s superiority was not huge, it was clinically significant, with a number needed to treat (NNT) of around 10 when compared with switching to bupropion. But the price of this higher response rate is a cluster of side effects, including weight gain, akathisia, and somnolence. In addition, these results may not generalize to non-VA populations, such as women of any age and younger men. Nonetheless, this large and well-designed study should encourage us to consider aripiprazole augmentation as a solid second-step strategy in depression treatment.
General Psychiatry
KEYWORDS antidepressants research_updates
Ricardo Arechiga, PharmD candidate (2018)

Can Strattera Improve Reading Skills in Children With Dyslexia?

More from this author
www.thecarlatreport.com
Issue Date: November 1, 2017
SUBSCRIBE NOW
Table Of Contents
Closing a Practice: Some Practical Suggestions
Financial Planning for Retirement
Aripiprazole Augmentation May Improve Remission Rates in MDD
Fluoxetine Plus CBT for Somatic Symptom Disorder
CME Post-Test - Retirement, TCPR, November 2017
Note From the Editor-in-Chief
Retirement Toolkits
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.